In contrast, other cancers like bladder cancer and liver hepatocellular carcinoma show instances of heterozygous amplification, potentially correlating with the higher expression levels and the poorer prognosis associated with MATN3 in these conditions. This evidence concerns the gene MATN3 and urinary bladder cancer.